)
)
Pardes Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Pardes Biosciences Inc
Access all reports
Pardes Biosciences Inc. is a biopharmaceutical company that was focused on the discovery, development, and commercialization of novel oral antiviral therapeutics. The company targeted life-threatening diseases, including its efforts against COVID-19. Pardes Biosciences operated as a clinical-stage company, which indicates its products were in the clinical trial phase and not yet available on the market. As of August 31, 2023, Pardes Biosciences was acquired by MediPacific, Inc., and it became a wholly owned subsidiary of MediPacific. Following the acquisition, the shares of Pardes Biosciences ceased trading and were delisted from the Nasdaq stock exchange.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
PRDS
Country
🇺🇸 United States